• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (from parent cell line).
  

PubMed=4028002
Harker W.G., Sikic B.I.
Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
Cancer Res. 45:4091-4096(1985)

PubMed=15816562
Wesolowska O., Paprocka M., Kozlak J., Motohashi N., Dus D., Michalak K.
Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening.
Anticancer Res. 25:383-389(2005)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22889595; DOI=10.1016/j.jprot.2012.07.047
Lin S.-T., Chou H.-C., Chang S.-J., Chen Y.-W., Lyu P.-C., Wang W.-C., Chang M.D.-T., Chan H.-L.
Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells.
J. Proteomics 75:5822-5847(2012)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)